Post-Authorisation Safety Study (PASS) to Evaluate the Risk of Malignancies in Patients with Myasthenia Gravis (MG) Treated with Efgartigimod

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No